The supplied source identifies an article in Frontiers in Immunology titled “Treatment of anti-GAD65 antibody-positive epilepsy and cerebellar ataxia with efgartigimod: a case report and literature review.” The material provided here from the journal website consists of navigation elements and journal scaffolding; the substantive manuscript text is not present in the supplied content. As a result, no case data, methods, results, or literature-review findings are available to summarize from this input.
The document title indicates that the published work includes at least one clinical case of a patient with anti-GAD65 antibody-positive neurologic disease manifesting as epilepsy and cerebellar ataxia. However, the supplied source content does not include any of the expected case-report elements: there are no details on patient age or sex, presenting symptoms, neurologic examination findings, diagnostic studies (for example, MRI, EEG, cerebrospinal fluid analysis, or antibody titers), comorbidities, or baseline functional status. Therefore, specific clinical information from the case cannot be reported here.
The title indicates the therapeutic agent used in the reported case is efgartigimod. The website content provided does not include any information on indication justification, dosing regimen, frequency, route of administration, concurrent treatments (such as antiseizure medications, immunotherapies, or supportive care), duration of therapy, monitoring strategies, or observed clinical or laboratory responses. No efficacy or safety outcomes related to efgartigimod are available in the supplied text.
The article is described as including a literature review in addition to the case report. The provided source material does not contain the literature-review content: no citations, no synthesis of previously reported cases or studies, and no comparative analysis are present in the supplied content. Consequently, we cannot summarize prior evidence, reported outcomes, or consensus on use of efgartigimod or other interventions for anti-GAD65-related epilepsy or cerebellar ataxia from this input.
A standard case report plus literature review would typically include authors’ interpretation of the individual case, discussion of potential mechanisms, assessment of treatment effect in the context of existing literature, and implications for clinical practice or research. The supplied source does not include any discussion text, so none of the authors’ arguments, hypotheses, or conclusions can be reproduced here. Any attempt to infer the authors’ interpretation would be speculative and is therefore omitted.
The primary limitation of the supplied source is that it contains only website navigation and journal shell content; the core manuscript text was not provided. Specific elements missing from the supplied content include but are not limited to:
Because these data are absent from the provided material, it is not possible to evaluate the case report’s internal validity, generalizability, or the degree of evidence supporting the treatment approach described in the title.
The supplied source confirms the existence of a published article with the given title in Frontiers in Immunology but does not provide substantive clinical content. Therefore, no evidence-based conclusions about the efficacy or safety of efgartigimod for anti-GAD65 antibody-positive epilepsy or cerebellar ataxia can be drawn from the material provided here. Clinicians and researchers seeking to assess the report’s findings should retrieve and review the full published article to examine the case details, methods, outcomes, and literature-review synthesis.
The supplied content does not include the article’s data-availability statement, ethics approval information, informed-consent details, author list, affiliations, or funding disclosures. These items are normally present in the full manuscript and are important for evaluating transparency and ethical conduct, but they were not reported in the provided source text.
Note on source limitations
This editorial summary is strictly limited to the content present in the supplied source excerpt. Where the manuscript text, data, and author statements were not provided, this summary explicitly indicates that those details were not reported in the available source. To obtain the complete clinical and scientific content, readers should access the full article on the Frontiers in Immunology website or contact the publisher for the full text.